Commentary: Ongoing debate over the safety of the different mumps vaccine strains impacts mumps disease control

International Journal of Epidemiology

Volumn 31, Issue 5, 2002, Pages 983-984

  Fullerton, K E ^a   Reef, S E ^a  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; MUMPS VACCINE;

ARTICLE; ASEPTIC MENINGITIS; COST BENEFIT ANALYSIS; DRUG COST; DRUG FORMULATION; DRUG SAFETY; ERADICATION THERAPY; HEALTH PROGRAM; HUMAN; INFECTION CONTROL; MEASLES; MUMPS; PRIORITY JOURNAL; RUBELLA; STRAIN DIFFERENCE; VIRUS STRAIN;

EID: 0036816430     PISSN: 03005771     EISSN: None     Source Type: Journal    
DOI: 10.1093/ije/31.5.983     Document Type: Article

References (15)

1. CDC. Recommendations of the International Task Force for Disease Eradication. MMWR 1993;42(RR-16).
2. da Silveira CM, Kmetzsch CI, Mohrdieck R, Fagundes Sperb R, Prevots DR. The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. Int J Epidemiol 2002;31:978-82.
3. Atkinson W, Wolfe C (eds). Epidemiology and Prevention of Vaccine-Preventable Diseases. 7th Edn. Atlanta, GA: Centres for Disease Control, 2002, p. 116.
4. Black S, Shinefield H, Ray P et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one to two-year old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatr Infect Dis J 1997;16:500-03.
5. Cizman M, Mozetic M, Radescek-Raker R et al. Aseptic meningitis after vaccination against measles and mumps. Pediatr Infect Dis J 1989;8: 302-08.
6. Galazaka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bull World Health Organ 1999;77:3-14.
7. UNICEF. 2002 Vaccine projections: Quantities and pricing. http://www.supply.unicef.dk/insideSD/2002ccine_jection.pdf. (accessed 07/10/2002).
8. Pan American Health Organization (PAHO). PAHO's revolving fund vaccines price for 2001. EpiNewsletter 2000;XXII(6):8.
9. Koplan JP, Preblud SR. A benefit-cost analysis of mumps vaccine. Am J Dis Child 1982;136:362-64.
10. White CC, Koplan JP, Orenstein WA. Benefits, risks, and costs of immunization for measles, mumps, and rubella. Am J Public Health 1985;75:739-44.
11. Slater PE, Roitman M, Costin C. Mumps incidence in Israel-Impact of the MMR vaccine. Public Health Rev 1991;18:88-93.
12. Arday DR, Kanjarpane DD, Kelley PW. Mumps in the US Army 1980-86: Should recruits be immunized? Am J Public Health 1989:79:471-74.
13. Hinman AR, Irons B, Lewis M, Kandola K. Economic analyses of rubella and rubella vaccines: a global review. Bull World Health Organ 2002;80:264-70.
14. World Health Organization. Mumps virus vaccines. Wkly Epidemiol Rec 2001;76:346-55.
15. da Cunha SS, Rodrigues LC, Barreto ML, Dourado I. Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain. Vaccine 2002;20:1106-12.